[12] Patent
[11] Patent No.:GC0007593  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126064
Date of the Decision to Grant the Patent:16/Apr/2018

[21] Application No.:GC 2014-26361

[22] Filing Date:3/2/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
6/2/2013
13154256.5

[72] Inventors:1- Christian GNAMM،2- Thorsten OOST،3- Stefan PETERS

[73] Owner: Boehringer Ingelheim International GmbH , Binger Strasse 173, 55216 , Ingelheim am Rhein, Germany

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/517; A61P 11/06, 19/02; C07D 239/70, 403/12, 487/04 (2006.01)

[56] Cited Documents:

-WO 2007/129060 A1 (ARGENTA DISCOVERY LTD [GB]; RAY NICHOLAS CHARLES [GB]; FINCH HARRY [GB) 15 November 2007  
Examiner: PH. Sultana K. AlOudah

[54] SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
[57] Abstract: This invention relates to substituted bicyclic dihydropyrimidinones of formula 1 1and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other autoimmune and allergic disorders, allograft rejection, and oncological diseases.
No. of claims: 15


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.